Amplifon S.p.A. stock (IT0004056880): Hearing aid leader reports steady growth

Amplifon S.p.A. maintains its position as a leading provider of hearing solutions, with a network spanning more than 5,000 stores across 26 countries. The company reported full-year 2025 revenue of €2.46 billion, up 8.3% on a constant currency basis, according to company filings as of March 2026. This growth reflects strong performance in mature markets like North America and Europe.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Amplifon S.p.A.: core business model

Amplifon S.p.A. specializes in hearing care, offering diagnosis, hearing aids, and related services through a vast retail network. Founded in 1948, the company has grown into a global player with a focus on personalized audiology solutions. Its model combines direct-to-consumer retail with B2B partnerships, serving over 2 million customers annually as per its 2025 annual report published in March 2026.

The business emphasizes innovation in digital hearing technologies and tele-audiology, adapting to aging populations worldwide. Amplifon operates under brands like Miracle-Ear in the US, providing accessibility for US investors interested in healthcare demographics.

Main revenue and product drivers for Amplifon S.p.A.

Hearing aid sales account for the majority of revenue, supplemented by maintenance services and accessories. In 2025, services grew 12% year-over-year, contributing to overall margins of 16.8% EBITDA, according to IR disclosures as of March 2026. North America represented 22% of group revenue, highlighting US market exposure.

Product innovation drives growth, with premium digital devices and AI-enhanced fittings boosting average selling prices. Amplifon's subscription models for aftercare further stabilize recurring income.

Industry trends and competitive position

The global hearing aid market is projected to reach $10 billion by 2028, fueled by demographics and OTC regulations in the US, per Statista data published in 2025. Amplifon competes with Sonova, Demant, and WS Audiology, holding a strong retail footprint advantage.

Amplifon's acquisition strategy, including recent US clinic expansions, bolsters its competitive edge. The firm's 18.7% like-for-like revenue growth in Q4 2025 underscores resilience amid supply chain challenges.

Why Amplifon S.p.A. matters for US investors

Amplifon generates significant revenue from the US via its Miracle-Ear brand, tapping into a $5 billion domestic market. US OTC hearing aid rules since 2022 have expanded access, benefiting retail-focused players like Amplifon. Its Milan listing offers US investors exposure to European healthcare stability with transatlantic growth.

Main revenue and product drivers for Amplifon S.p.A.

Strategic partnerships with device makers enhance product offerings. In 2025, Amplifon launched next-gen rechargeable aids, driving a 10% uptake increase in mature markets.

Conclusion

Amplifon S.p.A. demonstrates solid fundamentals in the growing hearing care sector, with robust revenue expansion and strategic US presence. Investors track its network growth and margin trajectory amid demographic tailwinds. Market dynamics, including regulatory shifts, continue to shape opportunities and challenges for the company.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.